Last reviewed · How we verify
NCT03982160
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
Phase 4 trial testing L-Arginine in Chronic Kidney Disease in 15 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | The University of Texas at Arlington |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 15 |
| Start date | 1 February 2018 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- L-Arginine — full drug profile →
- Placebo
Conditions studied
- Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Sponsor
The University of Texas at Arlington
Who can join
Adults 35 to 75, any sex, with Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future cardiovascular events in these patients. . The goal of this study is to determine whether overcoming the accumulation of endogenous ADMA with acute L-arginine infusion reduces SNA in CKD patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03982160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of L-Arginine
Trials testing the same drug.
- NCT07338682 — Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients · Phase 2 · recruiting
- NCT07347509 — Acute Effects of BCAA and L-Arginine on Performance in Elite Soccer Players · NA · completed
- NCT06947265 — Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile · Phase 4 · completed
- NCT05470998 — L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity · Phase 3 · completed
- NCT03625596 — Nutritional Supplements and Nitric Oxide Bioactivity · NA · completed
Other recruiting trials for Chronic Kidney Disease
Currently open trials in the same condition.
- NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
- NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
- NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
Other The University of Texas at Arlington trials
Trials by the same sponsor.
- NCT07219355 — Virtual Reality Lethal Means Safety Training · NA · recruiting
- NCT07313410 — Using Near-Infrared Light to Better Understand Peripheral Artery Disease · recruiting
- NCT07196436 — Asthma Intervention With Residential Ventilation and Air Cleaner (AIRVAC) Study · NA · recruiting
- NCT06857877 — Arlington Aging Study · recruiting
- NCT06497413 — Brain Vascular and Neurocognitive Health · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03982160 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas at Arlington
- Last refreshed: 3 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03982160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing